Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology · MELAS Syndrome

Does MELAS Syndrome Cause Hearing Loss?

At a Glance

Sensorineural hearing loss is a very common early symptom of MELAS syndrome due to the inner ear's high energy demands. While it cannot be prevented, it can be effectively managed with routine audiology screenings, hearing aids, cochlear implants, and avoiding ear-damaging medications.

Yes, it is very common to experience hearing loss with MELAS syndrome. Sensorineural hearing loss (damage to the inner ear or the nerve pathways to the brain) is one of the most frequent and characteristic early symptoms of the condition [1][2]. While there is currently no way to prevent the hearing loss from occurring or progressing, there are effective ways to manage it and protect the hearing you have [3][4].

Why Does MELAS Cause Hearing Loss?

MELAS syndrome is caused by a genetic mutation (most commonly the m.3243A>G mutation) that impairs the ability of your mitochondria to produce energy [5][6]. Your inner ear, particularly a structure called the cochlea (the spiral-shaped cavity that translates sound into nerve impulses), has extremely high energy demands [7]. Because the inner ear requires so much continuous energy to function properly, it is highly susceptible to the energy shortages caused by mitochondrial dysfunction [5][8].

What to Expect

Hearing loss associated with MELAS typically affects both ears and can begin in adolescence or early adulthood [9][10]. You may also experience tinnitus (a ringing, buzzing, or hissing sound in the ears) alongside the changes in your hearing.

The progression usually follows a distinct pattern: in the early stages, the decline is often gradual over years [5]. However, this gradual phase can be followed by a rapid decrease in hearing ability, leading to profound deafness in approximately half of affected individuals [5][11]. Because this symptom is so common and the timeline can vary significantly from person to person, proactive monitoring is a critical part of your routine medical care [2][12].

Management and Treatment Options

Currently, there are no proven medications or “mitochondrial cocktails” (like CoQ10 or L-arginine) that can prevent or slow the progression of sensorineural hearing loss in MELAS [4][3].

Important Note: Your doctor may still prescribe these supplements because they are critical for managing other MELAS symptoms, such as preventing life-threatening stroke-like episodes. Never stop taking your prescribed supplements without consulting your care team.

You and your care team can take actionable steps to manage your hearing and maintain your quality of life:

  • Routine Audiology Screening: Even if your hearing seems fine, getting an annual hearing test (or as frequently as your neurologist recommends) allows your care team to track any changes and adjust your management strategy promptly [2][13].
  • Avoid Ototoxic Medications: Certain drugs, particularly a class of antibiotics called aminoglycosides (which include common generic names like gentamicin, neomycin, and tobramycin), are ototoxic (harmful to the ear) and can severely exacerbate mitochondrial hearing loss [2][12]. Always ensure your doctors and pharmacists know you have a mitochondrial disorder before starting any new medication.
  • Protect Your Remaining Hearing: Avoid prolonged exposure to loud noises and use earplugs in loud environments to preserve your remaining healthy inner ear cells.
  • Hearing Aids: In the earlier stages of hearing loss, standard hearing aids can effectively amplify sound and help you communicate [2].
  • Cochlear Implants: For individuals who experience profound hearing loss and no longer benefit from hearing aids, cochlear implants (surgically implanted electronic devices that bypass the damaged inner ear to directly stimulate the hearing nerve) have been shown to be a safe and highly effective intervention [14][15]. Studies show they can significantly improve speech recognition for patients with MELAS [14].

Learning that profound hearing loss is a common risk of MELAS can be deeply overwhelming. Staying closely connected with your care team and utilizing these management strategies ensures you have an active plan for maintaining your communication and quality of life.

Common questions in this guide

Is hearing loss common in MELAS syndrome?
Yes, sensorineural hearing loss is one of the most common early symptoms of MELAS syndrome. It happens because the inner ear requires an enormous amount of continuous energy to function, making it highly vulnerable to mitochondrial dysfunction.
Can supplements or medications prevent hearing loss from MELAS?
Currently, no medications or mitochondrial supplements can prevent or slow the progression of hearing loss in MELAS. However, you should never stop taking your prescribed supplements, as they are critical for preventing other serious symptoms like stroke-like episodes.
Are there certain medications I should avoid to protect my hearing?
Yes, individuals with MELAS syndrome should avoid ototoxic medications, particularly a class of antibiotics called aminoglycosides like gentamicin and tobramycin. These drugs can severely worsen mitochondrial hearing loss.
What treatments are available for MELAS-related hearing loss?
In the early stages, standard hearing aids are used to effectively amplify sound. If the condition progresses to profound deafness, surgically placed cochlear implants are a safe and highly successful intervention to improve speech recognition and communication.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How frequently should I schedule routine audiology exams to establish a baseline and monitor for changes?
  2. 2.Are any of my current medications considered ototoxic, and should we discuss alternative options?
  3. 3.If my hearing loss progresses to a severe stage, who on my care team would coordinate an evaluation for cochlear implants?
  4. 4.What should I do if I notice a sudden change in my hearing or the onset of severe ringing in my ears?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Proton spectroscopy: a simple and useful tool in the investigation of mitochondrial disease.

    Nassif DV, Vasconcellos LFR

    Arquivos de neuro-psiquiatria 2022; (80(5)):543-544 doi:10.1590/0004-282X-ANP-2021-0422.

    PMID: 35486820
  2. 2

    Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes.

    Murakami K, Sakamoto K, Ishiguchi H, Ito H

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2023; (32(5)):107080 doi:10.1016/j.jstrokecerebrovasdis.2023.107080.

    PMID: 36933522
  3. 3

    The Mitochondrial m.3243A>G Mutation on the Dish, Lessons from In Vitro Models.

    Ryytty S, Hämäläinen RH

    International journal of molecular sciences 2023; (24(17)) doi:10.3390/ijms241713478.

    PMID: 37686280
  4. 4

    l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review.

    Stefanetti RJ, Ng YS, Errington L, et al.

    Neurology 2022; (98(23)):e2318-e2328 doi:10.1212/WNL.0000000000200299.

    PMID: 35428733
  5. 5

    Long-Term Progression and Rapid Decline in Hearing Loss in Patients with a Point Mutation at Nucleotide 3243 of the Mitochondrial DNA.

    Sakata A, Kashio A, Koyama H, et al.

    Life (Basel, Switzerland) 2022; (12(4)) doi:10.3390/life12040543.

    PMID: 35455034
  6. 6

    Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic.

    Pröbstel AK, Schaller A, Lieb J, et al.

    Neurology. Genetics 2016; (2(6)):e121 doi:10.1212/NXG.0000000000000121.

    PMID: 27878137
  7. 7

    Temporal bone histopathology in MELAS syndrome.

    Handzel O, Ungar OJ, Lee DJ, Nadol JB

    Laryngoscope investigative otolaryngology 2020; (5(1)):152-156 doi:10.1002/lio2.344.

    PMID: 32128442
  8. 8

    Molecular biomarkers correlate with brain grey and white matter changes in patients with mitochondrial m.3243A > G mutation.

    Evangelisti S, Gramegna LL, La Morgia C, et al.

    Molecular genetics and metabolism 2022; (135(1)):72-81 doi:10.1016/j.ymgme.2021.11.012.

    PMID: 34916127
  9. 9

    Severe clinical manifestation of mitochondrial disease due to the m.3243A>T variant: a case report of early-onset, multi-organ involvement and premature death.

    Gillespie H, Ng YS, Wood KM, et al.

    Journal of rare diseases (Berlin, Germany) 2025; (4(1)):47 doi:10.1007/s44162-025-00110-0.

    PMID: 40787093
  10. 10

    Teaching Video NeuroImages: MT-TL1 mutation presenting as chronic progressive external ophthalmoplegia.

    Parsons AM, Mehta SH, Acierno MD, Dhamija R

    Neurology 2019; (92(4)):e394 doi:10.1212/WNL.0000000000006817.

    PMID: 30665919
  11. 11

    MELAS Syndrome Presenting with Hypertrophic Cardiomyopathy and Advanced Heart Failure: A Multisystem Diagnostic Challenge.

    Dodulík J, Lazárová M, Kapsová E, Václavík J

    Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15031109.

    PMID: 41682788
  12. 12

    Mitochondrial DNA mutation "m.3243A>G"-Heterogeneous clinical picture for cardiologists ("m.3243A>G": A phenotypic chameleon).

    Niedermayr K, Pölzl G, Scholl-Bürgi S, et al.

    Congenital heart disease 2018; (13(5)):671-677 doi:10.1111/chd.12634.

    PMID: 30133155
  13. 13

    Haemorrhagic Transformation of a MELAS Stroke-Like Lesion.

    Bensaidane MR, Camden MC, Savard M

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2020; (47(1)):117-118 doi:10.1017/cjn.2019.317.

    PMID: 31648660
  14. 14

    Cochlear Implantation in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome: Case Presentation.

    Crundwell G, Kullar P, Bance M

    The journal of international advanced otology 2022; (18(1)):71-73 doi:10.5152/iao.2022.21316.

    PMID: 35193849
  15. 15

    Screening for Maternally Inherited Diabetes and Deafness in Large Cohorts of Hearing Impaired and Diabetic Patients.

    Varga L, Borecka S, Skopkova M, et al.

    Ear and hearing 2026; doi:10.1097/AUD.0000000000001780.

    PMID: 41664274

This page provides educational information about hearing loss in MELAS syndrome. Always consult your neurologist and audiologist for personalized management, and never change your prescribed medications without professional guidance.

Get notified when new evidence is published on MELAS.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.